Tansey Casey M purchased $199K of MOBI

Mobia Medical (MOBI) reported Q3 GAAP EPS of -$0.52 and revenue of $15.6M, up 73% Y/Y. The company raised its full-year 2026 revenue guidance to $57M-$57.5M from $54M-$56M, with $160.7M in cash as of September 30, 2026.

Mobia Medical (MOBI) reported Q3 earnings with a net loss of $17.3M ($0.52 per share), improved from last year. Gross margin rose to 83.2%. Operating expenses increased to $31.5M due to higher personnel costs. The company cited positive impacts from revised stroke recovery guidelines and expects to publish clinical evidence in 2027.

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Third Quarter 2026 Financial Results Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance Austin, Texas, November 5, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke

BTIG reiterated a Buy rating on Mobia Medical with a $19 price target, suggesting 115.7% upside from the Oct 19 close of $8.81. The firm cited improved reimbursement dynamics and strong clinical outcomes for the Vivistim System as key drivers for potential revenue growth and adoption.

Mobia Medical (MOBI) announced that its Vivistim Paired VNS System, the only FDA-approved device for this treatment, was included in the 2026 AHA stroke recovery guidelines. The guidelines recognize paired VNS as an option to improve upper-limb function in chronic stroke survivors. MOBI's stock is up 7.17% in pre-market trading at $11.36.

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.